Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report released on Thursday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald raised their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $15.61 on Thursday. The stock has a market capitalization of $709.79 million, a P/E ratio of -14.73 and a beta of 4.08. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business’s 50 day moving average is $16.70 and its two-hundred day moving average is $10.89.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CAPR. Bank of New York Mellon Corp increased its holdings in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. Rhumbline Advisers acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Main Street Financial Solutions LLC increased its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at approximately $426,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.